☆ 4.7 Article

P2Y12 Inhibitor Monotherapy or Dual Antiplatelet Therapy After Complex Percutaneous Coronary Interventions

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Cardiac & Cardiovascular Systems

Evolution of drug-eluting coronary stents: a back-and-forth journey from the bench to bedside

Johny Nicolas et al.

Summary: Coronary stents have revolutionized the treatment of coronary artery disease. The introduction of new-generation drug-eluting stents has greatly improved the safety and efficacy compared to bare-metal stents. There are now over 20 different DES types available, each with its unique features and characteristics. The clinical implications of stent design in high-risk subsets of patients are also discussed.

CARDIOVASCULAR RESEARCH (2023)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

2021 ACC/AHA/SCAT Guideline for Coronary Artery Revascularization

Sripal Bangalore et al.

Summary: This article introduces the importance and application of coronary artery revascularization guidelines, which provide a patient-centric approach for treating patients with significant coronary artery disease. The guidelines are supported by relevant literature.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT trial sub-analysis

Marco Valgimigli et al.

Summary: This study assessed the effects of abbreviated dual antiplatelet therapy (DAPT) compared to standard DAPT in high bleeding risk (HBR) patients who received biodegradable-polymer sirolimus-eluting stents. The study found that in HBR patients free from recurrent ischemic events, abbreviated DAPT was associated with similar adverse clinical events and lower bleeding rates compared to standard DAPT, regardless of the complexity of the intervention or patient condition.

EUROPEAN HEART JOURNAL (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome The STOPDAPT-2 ACS Randomized Clinical Trial

Hirotoshi Watanabe et al.

Summary: In patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI), clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy (DAPT) did not demonstrate noninferiority to 12 months of DAPT for the composite end point of cardiovascular and bleeding events.

JAMA CARDIOLOGY (2022)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

P2Y(12) inhibitor monotherapy in patients undergoing percutaneous coronary intervention

Davide Capodanno et al.

Summary: The evolution of stent design has reduced the risk of stent thrombosis after PCI, potentially shortening the duration of dual antiplatelet therapy. Recent studies suggest that P2Y(12) inhibitor monotherapy after PCI may be safer and more effective than dual antiplatelet therapy.

NATURE REVIEWS CARDIOLOGY (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

Jean-Philippe Collet et al.

EUROPEAN HEART JOURNAL (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Prognostic Implications of Declining Hemoglobin Content in Patients Hospitalized With Acute Coronary Syndromes

Sergio Leonardi et al.

Summary: In patients with ACS undergoing invasive management, in-hospital hemoglobin drop ≥3 g/dl, even in the absence of overt bleeding, is common and independently associated with an increased risk for 1-year mortality.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Very Short Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Patients Who Underwent Complex Percutaneous Coronary Intervention Insight From the STOPDAPT-2 Trial

Ko Yamamoto et al.

Summary: In both complex and noncomplex PCI patients, clopidogrel monotherapy after 1-month DAPT showed comparable effects to 12-month DAPT on cardiovascular outcomes without significant interactions. Additionally, the 1-month DAPT group had significantly lower bleeding risk compared to the 12-month DAPT group regardless of PCI complexity.

CIRCULATION-CARDIOVASCULAR INTERVENTIONS (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

P2Y12 inhibitor monotherapy in complex percutaneous coronary intervention: A post-hoc analysis of SMART-CHOICE randomized clinical trial

Ji Woong Roh et al.

Summary: The study found that P2Y(12) inhibitor monotherapy with clopidogrel following short-term DAPT did not increase the risk of ischemic events in patients undergoing complex PCI.

CARDIOLOGY JOURNAL (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Ticagrelor Monotherapy Versus Ticagrelor With Aspirin in Acute Coronary Syndrome Patients With a High Risk of Ischemic Events

Seung-Jun Lee et al.

Summary: In patients with acute coronary syndrome at high risk of ischemia, there is no significant difference in clinical outcomes between using ticagrelor monotherapy after 3-month DAPT compared to ticagrelor-based 12-month DAPT.

CIRCULATION-CARDIOVASCULAR INTERVENTIONS (2021)

添加到收藏夹

Article Medicine, General & Internal

Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk

Marco Valgimigli et al.

Summary: The study showed that one month of dual antiplatelet therapy was noninferior to continuing therapy for at least 2 additional months in terms of net adverse clinical events and major adverse cardiac or cerebral events in patients with high risk of bleeding after drug-eluting stent implantation; abbreviated therapy also resulted in a lower incidence of major or clinically relevant nonmajor bleeding.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials

Marco Valgimigli et al.

Summary: The study assessed the risks and benefits of P2Y(12) inhibitor monotherapy compared with dual antiplatelet therapy, finding that P2Y(12) inhibitor monotherapy was associated with lower risk of primary ischemic endpoints and lower bleeding risk compared to DAPT.

BMJ-BRITISH MEDICAL JOURNAL (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Impact of clinical presentation on bleeding risk a ter percutaneous coronary intervention and implications for the ARC-HBR definition

Felice Gragnano et al.

Summary: The study found that patients with acute coronary syndrome (ACS) undergoing PCI have a higher risk of bleeding, especially within 30 days post-PCI. The ARC-HBR score had lower predictive ability in ACS patients compared to those with chronic coronary syndrome (CCS), but its performance slightly improved when ACS was considered as an additional minor risk criterion.

EUROINTERVENTION (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Ticagrelor With or Without Aspirin After Complex Percutaneous Coronary Intervention

George Dangas et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome The TICO Randomized Clinical Trial

Byeong-Keuk Kim et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting

Francesco Costa et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial

Patrick W. Serruys et al.

EUROPEAN HEART JOURNAL (2019)

添加到收藏夹

Article Medicine, General & Internal

RoB 2: a revised tool for assessing risk of bias in randomised trials

Jonathan A. C. Sterne et al.

BMJ-BRITISH MEDICAL JOURNAL (2019)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Ticagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting Coronary Stenting

Anna Franzone et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)

Marco Valgimigli et al.

EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY (2018)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Impact of percutaneous coronary intervention extent, complexity and platelet reactivity on outcomes after drug-eluting stent implantation

Philippe Genereux et al.

INTERNATIONAL JOURNAL OF CARDIOLOGY (2018)

添加到收藏夹

Article Medicine, General & Internal

Effect of Ticagrelor Plus Aspirin, Ticagrelor Alone, or Aspirin Alone on Saphenous Vein Graft Patency 1 Year After Coronary Artery Bypass Grafting A Randomized Clinical Trial

Qiang Zhao et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)

添加到收藏夹

Article Medicine, General & Internal

Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials

Francesco Costa et al.

LANCET (2017)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents

James B. Hermiller et al.

JACC-CARDIOVASCULAR INTERVENTIONS (2016)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Efficacy and Safety of Dual Antiplatelet Therapy After Complex PCI

Gennaro Giustino et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents Insights From the Xience V Coronary Stent System Trials

Philippe Genereux et al.

CIRCULATION-CARDIOVASCULAR INTERVENTIONS (2015)

添加到收藏夹

Review Medicine, General & Internal

Preferred Reporting Items for a Systematic Review and Meta-analysis of Individual Participant Data The PRISMA-IPD Statement

Lesley A. Stewart et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Endeavour zotarolimus-eluting stent reduces stent thrombosis and improves clinical outcomes compared with cypher sirolimus-eluting stent: 4-year results of the PROTECT randomized trial

William Wijns et al.

EUROPEAN HEART JOURNAL (2014)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.